Search

Mexiletine

Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties.

Abetimus

Abetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.

Arbaclofen Placarbil

It was discovered, and has been patented by XenoPort as a new chemical entity with an improved pharmacokinetic profile compared to baclofen, which allows for sustained release properties. … by XenoPort in 2011 for the treatment of GERD.

Picoplatin

It causes apoptosis (cell death) by binding to DNA and interfering with DNA replication and transcription.

Eplontersen

[A262975] Hereditary transthyretin-mediated amyloidosis is caused primarily by pathogenic variants of the TTR gene, leading to the formation and thus accumulation of insoluble and misfolded amyloid in … multiple organs, although wild-type misfolded TTR has also been observed to contribute to the disease pathophysiology.

Aluminium phosphate

Phleum pratense pollen

Phleum pratense pollen allergenic extract is used in allergenic testing.

Desogestrel

[A176342] The first approved drug containing desogestrel was developed by Organon USA Inc in 1972 and FDA approved in 1992.[L5762]

LetibotulinumtoxinA

[A249920] It was subsequently approved by the FDA in 1992 for use in aesthetic procedures and has since become one of the most popular cosmetic procedures worldwide.

Dapoxetine

In a phase II proof-of-concept study conducted by PPD, dapoxetine demonstrated a statistically significant increase in ejaculatory latency when compared to placebo. … In October 2005, the company received a FDA Non-Approvable letter from the FDA, at which time they planned to work with regulators to address outstanding questions.